排卵障害の診断の世界市場

排卵障害の診断の世界市場は2030年までに7億850万米ドルに達する見込み

2024年に5億4,410万米ドルと推定される排卵障害の診断の世界市場は、2030年には7億850万米ドルに達し、分析期間2024～2030年のCAGRは4.5%で成長すると予測されます。本レポートで分析したセグメントの1つである多嚢胞性卵巣症候群は、CAGR 4.5%を記録し、分析期間終了時には1億8,750万米ドルに達すると予測されます。高プロラクチン血症分野の成長率は、分析期間中CAGR 4.4％と推定されます。

米国市場は1億4,820万米ドルと推定、中国はCAGR 8.1％で成長すると予測

米国の排卵障害の診断市場は、2024年に1億4,820万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.1%として、2030年までに1億4,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.5%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の排卵障害の診断市場- 主要動向と促進要因まとめ

なぜ排卵障害の正確な診断が生殖医療管理において重要なのか？

排卵障害は、多嚢胞性卵巣症候群（PCOS）や視床下部無月経から黄体期不全や早発卵巣不全に至るまで、世界的に女性不妊症の主な原因の1つとなっています。正確な診断は、不妊治療成績を向上させるだけでなく、長期的な健康に影響を及ぼす根本的な代謝、内分泌、ホルモンの不均衡を特定するためにも不可欠です。生殖に関する意識が高まり、妊娠の遅れが増加する中、排卵障害の早期かつ信頼性の高い診断ツールに対する需要は着実に高まっています。

診断には、ホルモン測定（FSH、LH、エストラジオール、プロゲステロン）、超音波検査、排卵予測キット（OPK）、基礎体温の追跡、抗ミュラーホルモン（AMH）検査による卵巣予備能評価などを総合的に組み合わせる必要があります。臨床の場では、経膣超音波検査と子宮内膜生検が卵胞発育の追跡と排卵周期の確認に用いられています。早期スクリーニング、個別化された不妊治療、周期モニタリングへのシフトは、特に不妊治療計画や生殖補助医療を受けている女性の間で、検査室ベースと自宅診断技術の両方の採用を増加させています。

技術の進歩と家庭用検査キットはどのように診断経路を変えているのか？

ホルモン測定法の感度、非侵襲的画像診断、デジタルトラッキングの進歩により、排卵障害の診断がより身近で正確になりつつあります。自動免疫測定プラットフォーム、ポイントオブケア分析装置、AIベースの排卵トラッカーは、より迅速で個別化された診断決定を容易にしています。不妊治療用ウェアラブルやコネクテッドデバイスは現在、皮膚温、心拍変動、尿や唾液中のホルモン代謝物などの生理学的指標をモニターし、臨床的精度を高めながらリアルタイムの排卵に関する洞察を提供しています。

LHサージ検出を利用した排卵予測のための家庭用診断キットは、デジタル表示、Bluetooth同期、アプリベースの排卵カレンダーなど、より洗練されたものになってきています。これらの機器は、月経不順や妊娠のタイミングを追跡する女性にとって、プライバシーが守られ、便利で使いやすいです。一方、遠隔医療プラットフォームと自宅診断の統合により、ユーザーは不妊治療の専門家と周期データを共有することができ、不妊治療評価と介入への障壁を減らすハイブリッド・ケア・モデルが可能になります。

なぜライフスタイルの変化、啓発キャンペーン、保険政策が診断の普及を形成しているのか？

ストレスの増加、肥満、睡眠不足、座りっぱなしの行動など、現代のライフスタイルの変化は、特に都市環境に住む女性や出産を延期している女性の間で、排卵機能障害の増加の一因となっています。公衆衛生キャンペーンや生殖に関する健康教育は、排卵に関連する症状に対する認識を高め、早期診断を促しています。非営利団体や不妊擁護団体は、月経の健康にまつわる言説を増幅させ、スティグマをなくし、より頻繁な臨床受診につなげています。

特に先進国市場では、診断検査に対する保険償還が、排卵障害の早期スクリーニングを促す上で重要な役割を果たしています。不妊評価の保険適用、雇用者負担の不妊治療給付金、女性の健康診断にホルモン評価を含めることで、診断の利用しやすさが拡大しています。低・中所得国では、妊産婦の健康やデジタルヘルス・インフラに対する政府資金の増加も、月経・排卵障害診断のアウトリーチを促進しています。

排卵障害の診断サービスの世界的拡大の原動力は？

排卵障害の診断市場の成長は、不妊率の上昇、リプロダクティブヘルスに対する一般市民の意識の高まり、PCOSなどの内分泌疾患の有病率の増加など、いくつかの要因によって牽引されています。主な成長要因は、家族計画の遅延傾向の高まりであり、そのため早期の不妊スクリーニングと個別化された排卵モニタリングが必要となっています。また、女性医療クリニック、不妊治療センター、デジタル生殖医療プラットフォームの拡大により、地域全体で診断ツールへのアクセスが増加しています。

さらに、AIを活用した周期予測アルゴリズム、バイオセンシング技術、不妊治療追跡アプリとの統合の進歩により、排卵の健康状態を長期的にモニタリングするための強固なエコシステムが構築されつつあります。非侵襲的診断キットやモバイル健康機器に対する規制当局の承認は、消費者グレードの診断イノベーションの迅速な市場参入を支えています。

消費者の意識の高まり、技術革新、多チャンネル提供モデルにより、排卵障害診断は女性の予防・生殖ヘルスケアに不可欠な要素になると思われます。個別化医療、デジタルヘルス、ホルモン分析の融合が進むことで、この進化する世界市場において診断ソリューションの精度と到達範囲の両方が向上し続けると思われます。

セグメント

排卵障害（多嚢胞性卵巣症候群、高プロラクチン血症、黄体期不全、視床下部機能不全、腫瘍、自己免疫性卵巣炎、原発性卵巣不全、抵抗性卵巣症候群、その他の排卵障害）、診断タイプ（ホルモンのラボ検査、下垂体および視床下部のCTスキャンおよびMRIスキャン、卵巣生検、その他の診断タイプ）、エンドユーザー（病院、婦人科クリニック、診断センター、その他のエンドユーザー）

調査対象企業の例（注目の合計48社）

• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Canon Medical Systems Corporation
• Carestream Health
• Fujifilm Holdings Corporation
• GE Healthcare
• Genova Diagnostics
• Hologic, Inc.
• LabCorp
• Medtronic plc
• PerkinElmer Inc.
• Quest Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Swiss Precision Diagnostics GmbH
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Toshiba Medical Systems Corporation

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ovulation Disorder Diagnosis Market to Reach US$708.5 Million by 2030

The global market for Ovulation Disorder Diagnosis estimated at US$544.1 Million in the year 2024, is expected to reach US$708.5 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Polycystic Ovarian Syndrome, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$187.5 Million by the end of the analysis period. Growth in the Hyperprolactinemia segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$148.2 Million While China is Forecast to Grow at 8.1% CAGR

The Ovulation Disorder Diagnosis market in the U.S. is estimated at US$148.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$146.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Ovulation Disorder Diagnosis Market - Key Trends & Drivers Summarized

Why Is Accurate Diagnosis of Ovulation Disorders Critical in Reproductive Health Management?

Ovulation disorders-ranging from polycystic ovary syndrome (PCOS) and hypothalamic amenorrhea to luteal phase defects and premature ovarian insufficiency-represent one of the leading causes of female infertility globally. Accurate diagnosis is vital not only for improving fertility outcomes but also for identifying underlying metabolic, endocrine, and hormonal imbalances that impact long-term health. With increasing awareness of reproductive wellness and rising incidences of delayed pregnancies, the demand for early and reliable diagnostic tools for ovulation disorders is growing steadily.

Diagnosis involves a comprehensive combination of hormonal assays (FSH, LH, estradiol, progesterone), ultrasonography, ovulation prediction kits (OPKs), basal body temperature tracking, and ovarian reserve assessments through anti-Mullerian hormone (AMH) tests. In clinical settings, transvaginal ultrasounds and endometrial biopsies are used to track follicular development and confirm ovulatory cycles. The shift toward early screening, personalized fertility treatment, and cycle monitoring is increasing the adoption of both laboratory-based and at-home diagnostic technologies, particularly among women undergoing fertility planning or assisted reproductive treatments.

How Are Technology Advancements and At-Home Testing Kits Transforming Diagnostic Pathways?

Advances in hormonal assay sensitivity, non-invasive imaging, and digital tracking are making ovulation disorder diagnostics more accessible and precise. Automated immunoassay platforms, point-of-care analyzers, and AI-based ovulation trackers are facilitating faster, personalized diagnostic decisions. Fertility wearables and connected devices now monitor physiological indicators such as skin temperature, heart rate variability, and hormone metabolites in urine or saliva, offering real-time ovulation insights with increasing clinical accuracy.

At-home diagnostic kits for ovulation prediction-utilizing LH surge detection-are becoming more sophisticated with digital readouts, Bluetooth syncing, and app-based fertility calendars. These devices offer privacy, convenience, and ease-of-use for women tracking menstrual irregularities or timing conception. Meanwhile, the integration of telemedicine platforms with at-home diagnostics allows users to share cycle data with fertility specialists, enabling hybrid care models that reduce barriers to fertility evaluation and intervention.

Why Are Lifestyle Shifts, Awareness Campaigns, and Insurance Policies Shaping Diagnostic Uptake?

Modern lifestyle shifts-including increased stress, obesity, poor sleep, and sedentary behavior-have contributed to a rise in ovulatory dysfunctions, particularly among women in urban environments and those delaying childbirth. Public health campaigns and reproductive health education are raising awareness of ovulation-related symptoms and encouraging early diagnosis. Non-profit organizations and fertility advocacy groups are amplifying discourse around menstrual health, leading to de-stigmatization and more frequent clinical consultations.

Reimbursement for diagnostic testing, especially in developed markets, is playing a crucial role in encouraging early screening for ovulatory disorders. Insurance coverage for infertility evaluations, employer-sponsored fertility benefits, and inclusion of hormonal assessments in women’s health check-ups are expanding diagnostic accessibility. In low- and middle-income countries, increased government funding for maternal health and digital health infrastructure is also facilitating outreach for menstrual and ovulatory disorder diagnostics.

What’s Driving the Global Expansion of Ovulation Disorder Diagnosis Services?

The growth in the ovulation disorder diagnosis market is driven by several factors including rising infertility rates, greater public awareness of reproductive health, and the increasing prevalence of endocrine disorders such as PCOS. A major growth driver is the growing trend of delayed family planning, which necessitates early fertility screening and personalized ovulation monitoring. The expansion of women’s health clinics, fertility centers, and digital reproductive health platforms is also increasing access to diagnostic tools across geographies.

Further, advancements in AI-powered cycle prediction algorithms, bio-sensing technology, and integration with fertility tracking apps are creating a robust ecosystem for longitudinal monitoring of ovulation health. Regulatory approvals for non-invasive diagnostic kits and mobile health devices are supporting faster market entry for consumer-grade diagnostic innovations.

With growing consumer awareness, technology innovation, and multi-channel delivery models, ovulation disorder diagnostics are set to become an integral component of women’s preventive and reproductive healthcare. The ongoing convergence of personalized medicine, digital health, and hormonal analytics will continue to elevate both the precision and reach of diagnostic solutions in this evolving global market.

SCOPE OF STUDY:

The report analyzes the Ovulation Disorder Diagnosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Ovulation Disorder (Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome, Other Ovulation Disorders); Diagnosis Type (Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy, Other Diagnosis Types); End-Use (Hospitals, Gynecological Clinics, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Canon Medical Systems Corporation
• Carestream Health
• Fujifilm Holdings Corporation
• GE Healthcare
• Genova Diagnostics
• Hologic, Inc.
• LabCorp
• Medtronic plc
• PerkinElmer Inc.
• Quest Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Swiss Precision Diagnostics GmbH
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Toshiba Medical Systems Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Ovulation Disorder Diagnosis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Infertility and Hormonal Imbalances Drives Demand for Ovulation Disorder Diagnostics
  • Expansion of Fertility Awareness and Reproductive Planning Throws the Spotlight on Home and Clinical Diagnostic Tools
  • OEM Innovation in Digital Ovulation Tracking and Hormone-Based Test Kits Enhances Early Diagnosis Accuracy
  • Growth in PCOS and Endocrine Disorder Cases Propels Demand for Targeted Ovulatory Function Testing
  • OEM Development of Multiplex Hormone Panels and Saliva-Based Kits Supports Non-Invasive Diagnosis
  • Regulatory Support for Direct-to-Consumer Fertility Testing Encourages Broader Market Participation
  • OEM Integration of AI and Predictive Analytics in Fertility Apps Enhances Cycle Forecasting and Monitoring
  • Increased Awareness Campaigns and Fertility Education Programs Drive Routine Ovulation Monitoring
  • Growth in Assisted Reproductive Technologies Expands Need for Pre-Treatment Ovulatory Assessment
  • OEM Collaboration With OB/GYN Clinics and IVF Centers Supports Lab-to-Home Diagnostic Models
  • Surge in Subscription-Based and Connected Health Devices Enhances Ongoing Hormonal Monitoring
  • OEM Emphasis on Cycle Irregularity Management and Predictive Biomarkers Drives Personalized Diagnostic Tools
  • Rising Demand for Menstrual Health Tracking Among Young Adults Supports Early Detection
  • OEM Focus on Auto-Calibration and Real-Time Results Improves User Trust in At-Home Ovulation Diagnostics
  • Expansion of Insurance Coverage and Reimbursement in Select Markets Strengthens Accessibility of Hormonal Assays
  • Growth in E-Commerce and Femtech Platforms Supports Omnichannel Sales of Ovulation Testing Products
  • OEM Investment in Low-Cost Diagnostic Platforms Expands Reach in Low-Resource Settings
  • Clinical Adoption of Luteinizing Hormone and Progesterone Monitoring Enhances Diagnostic Pathways
  • Challenges in Differentiating Between Ovulatory Dysfunction Types Drive Advanced Endocrinological Testing
  • OEM Focus on Reproducibility and Test Sensitivity Enhances Diagnostic Confidence for Healthcare Providers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ovulation Disorder Diagnosis Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ovulation Disorder Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ovulation Disorder Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Polycystic Ovarian Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Polycystic Ovarian Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Polycystic Ovarian Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hyperprolactinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Hyperprolactinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Hyperprolactinemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Luteal Phase Defect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Luteal Phase Defect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Luteal Phase Defect by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hypothalamus Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hypothalamus Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hypothalamus Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Autoimmune Oophoritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Autoimmune Oophoritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Autoimmune Oophoritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Primary Ovarian Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Primary Ovarian Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Primary Ovarian Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Resistant Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Resistant Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Resistant Ovary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Ovulation Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Ovulation Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Ovulation Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Laboratory Testing of Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Laboratory Testing of Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Laboratory Testing of Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for CT Scan & MRI Scan of Pituitary Gland & Hypothalamus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for CT Scan & MRI Scan of Pituitary Gland & Hypothalamus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for CT Scan & MRI Scan of Pituitary Gland & Hypothalamus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Ovarian Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Ovarian Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Ovarian Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Gynecological Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Gynecological Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Gynecological Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Ovulation Disorder Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Ovulation Disorder Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 131: UK Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 155: Russia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Russia Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Russia 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Europe Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Europe 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 185: Australia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Australia Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Australia 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 188: India Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 194: India Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: India Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: India 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 203: South Korea Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: South Korea Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: South Korea 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Asia-Pacific Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Ovulation Disorder Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 224: Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Latin America Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 233: Argentina Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Argentina Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Argentina 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 242: Brazil Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Brazil Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Brazil 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 251: Mexico Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Mexico Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Mexico 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Latin America Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Latin America 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Ovulation Disorder Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 272: Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Middle East Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 281: Iran Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Iran Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Iran 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 290: Israel Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Israel Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Israel 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Saudi Arabia Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Saudi Arabia 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 308: UAE Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: UAE Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: UAE 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Middle East Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Middle East 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Ovulation Disorder Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Ovulation Disorder Diagnosis by Ovulation Disorder - Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Ovulation Disorder Diagnosis by Ovulation Disorder - Percentage Breakdown of Value Sales for Polycystic Ovarian Syndrome, Hyperprolactinemia, Luteal Phase Defect, Hypothalamus Dysfunction, Tumors, Autoimmune Oophoritis, Primary Ovarian Failure, Resistant Ovary Syndrome and Other Ovulation Disorders for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Ovulation Disorder Diagnosis by Diagnosis Type - Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Ovulation Disorder Diagnosis by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Testing of Hormones, CT Scan & MRI Scan of Pituitary Gland & Hypothalamus, Ovarian Biopsy and Other Diagnosis Types for the Years 2015, 2025 & 2030
  • TABLE 326: Africa Recent Past, Current & Future Analysis for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Africa Historic Review for Ovulation Disorder Diagnosis by End-Use - Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Africa 15-Year Perspective for Ovulation Disorder Diagnosis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Gynecological Clinics, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION